O	0	10	Expression	Expression	NN	B-NP
O	11	13	of	of	IN	B-PP
O	14	18	HER2	HER2	NN	B-NP
O	19	22	and	and	CC	I-NP
O	23	33	bradykinin	bradykinin	NN	I-NP
O	34	36	B1	B1	NN	I-NP
O	37	46	receptors	receptor	NNS	I-NP
O	47	49	in	in	IN	B-PP
B-Pathological_formation	50	59	precursor	precursor	NN	B-NP
I-Pathological_formation	60	67	lesions	lesion	NNS	I-NP
O	68	70	of	of	IN	B-PP
B-Cancer	71	82	gallbladder	gallbladder	NN	B-NP
I-Cancer	83	92	carcinoma	carcinoma	NN	I-NP
O	92	93	.	.	.	O

O	95	98	AIM	AIM	NN	B-NP
O	98	99	:	:	:	O
O	100	102	To	To	TO	B-VP
O	103	112	determine	determine	VB	I-VP
O	113	116	the	the	DT	B-NP
O	117	127	expression	expression	NN	I-NP
O	128	130	of	of	IN	B-PP
O	131	135	HER2	HER2	NN	B-NP
O	136	139	and	and	CC	O
O	140	150	bradykinin	bradykinin	NN	B-NP
O	151	152	B	B	NN	I-NP
O	152	153	(	(	(	O
O	153	154	1	1	CD	B-NP
O	154	155	)	)	)	O
O	156	165	receptors	receptor	NNS	B-NP
O	166	167	(	(	(	O
O	167	168	B	B	NN	B-NP
O	168	169	(	(	(	O
O	169	170	1	1	CD	B-NP
O	170	171	)	)	)	O
O	171	172	R	R	NN	B-NP
O	172	173	)	)	)	O
O	174	176	in	in	IN	B-PP
O	177	180	the	the	DT	B-NP
O	181	184	two	two	CD	I-NP
O	185	195	pathogenic	pathogenic	JJ	I-NP
O	196	202	models	model	NNS	I-NP
O	203	205	of	of	IN	B-PP
B-Cancer	206	217	gallbladder	gallbladder	NN	B-NP
I-Cancer	218	224	cancer	cancer	NN	I-NP
O	224	225	:	:	:	O
O	226	229	the	the	DT	B-NP
B-Cancer	230	240	metaplasia	metaplasia	NN	I-NP
I-Cancer	240	241	-	-	HYPH	B-NP
I-Cancer	241	250	dysplasia	dysplasia	NN	I-NP
I-Cancer	250	251	-	-	HYPH	I-NP
I-Cancer	251	260	carcinoma	carcinoma	NN	I-NP
O	261	264	and	and	CC	O
O	265	268	the	the	DT	B-NP
B-Cancer	269	276	adenoma	adenoma	NN	I-NP
I-Cancer	276	277	-	-	HYPH	B-NP
I-Cancer	277	286	carcinoma	carcinoma	NN	I-NP
O	287	295	pathways	pathway	NNS	I-NP
O	295	296	.	.	.	O

O	297	304	METHODS	METHODS	NNS	B-NP
O	304	305	:	:	:	O
O	306	314	Receptor	Receptor	NN	B-NP
O	315	323	proteins	protein	NNS	I-NP
O	324	328	were	be	VBD	B-VP
O	329	339	visualized	visualize	VBN	I-VP
O	340	342	by	by	IN	B-PP
O	343	363	immunohistochemistry	immunohistochemistry	NN	B-NP
O	364	366	on	on	IN	B-PP
O	367	368	5	5	CD	B-NP
O	368	369	-	-	HYPH	I-NP
O	369	372	mum	mum	NN	I-NP
B-Multi-tissue_structure	373	381	sections	section	NNS	I-NP
O	382	384	of	of	IN	B-PP
O	385	393	paraffin	paraffin	NN	B-NP
O	393	394	-	-	HYPH	O
O	394	402	embedded	embed	VBN	B-NP
B-Tissue	403	409	tissue	tissue	NN	I-NP
O	409	410	.	.	.	O

O	411	421	Expression	Expression	NN	B-NP
O	422	424	of	of	IN	B-PP
O	425	429	both	both	DT	B-NP
O	430	439	receptors	receptor	NNS	I-NP
O	440	443	was	be	VBD	B-VP
O	444	451	studied	study	VBN	I-VP
O	452	454	in	in	IN	B-PP
B-Cancer	455	461	biopsy	biopsy	NN	B-NP
I-Cancer	462	469	samples	sample	NNS	I-NP
O	470	474	from	from	IN	B-PP
O	475	477	92	92	CD	B-NP
O	478	486	patients	patient	NNS	I-NP
O	487	488	(	(	(	O
O	488	489	6	6	CD	B-NP
O	490	495	males	male	NNS	I-NP
O	496	499	and	and	CC	O
O	500	502	86	86	CD	B-NP
O	503	510	females	female	NNS	I-NP
O	510	511	;	;	:	O
O	512	515	age	age	NN	B-NP
O	516	523	ranging	range	VBG	B-VP
O	524	528	from	from	IN	B-PP
O	529	531	28	28	CD	B-NP
O	532	534	to	to	TO	B-PP
O	535	537	86	86	CD	B-NP
O	538	543	years	year	NNS	I-NP
O	543	544	,	,	,	O
O	545	549	mean	mean	VB	B-VP
O	550	552	56	56	CD	B-NP
O	553	558	years	year	NNS	I-NP
O	558	559	)	)	)	O
O	559	560	.	.	.	O

O	561	565	High	High	JJ	B-NP
O	566	570	HER2	HER2	NN	I-NP
O	571	581	expression	expression	NN	I-NP
O	582	584	in	in	IN	B-PP
B-Cancer	585	594	specimens	specimen	NNS	B-NP
O	595	598	was	be	VBD	B-VP
O	599	611	additionally	additionally	RB	I-VP
O	612	624	investigated	investigate	VBN	I-VP
O	625	627	by	by	IN	B-PP
O	628	640	fluorescence	fluorescence	NN	B-NP
O	641	643	in	in	FW	B-NP
O	644	648	situ	situ	FW	I-NP
O	649	662	hybridization	hybridization	NN	I-NP
O	662	663	.	.	.	O

B-Cell	664	668	Cell	Cell	NN	B-NP
O	669	682	proliferation	proliferation	NN	I-NP
O	683	685	in	in	IN	B-PP
O	686	690	each	each	DT	B-NP
B-Cancer	691	697	sample	sample	NN	I-NP
O	698	701	was	be	VBD	B-VP
O	702	710	assessed	assess	VBN	I-VP
O	711	713	by	by	IN	B-PP
O	714	719	using	use	VBG	B-VP
O	720	723	the	the	DT	B-NP
O	724	726	Ki	Ki	NN	I-NP
O	726	727	-	-	HYPH	B-NP
O	727	729	67	67	CD	I-NP
O	730	743	proliferation	proliferation	NN	I-NP
O	744	750	marker	marker	NN	I-NP
O	750	751	.	.	.	O

O	752	759	RESULTS	RESULTS	NNS	B-NP
O	759	760	:	:	:	O
O	761	765	HER2	HER2	NN	B-NP
O	766	774	receptor	receptor	NN	I-NP
O	775	782	protein	protein	NN	I-NP
O	783	786	was	be	VBD	B-VP
O	787	793	absent	absent	JJ	B-ADJP
O	794	796	in	in	IN	B-PP
B-Cancer	797	805	adenomas	adenoma	NNS	B-NP
O	806	809	and	and	CC	B-PP
O	810	812	in	in	IN	B-PP
O	813	819	normal	normal	JJ	B-NP
B-Tissue	820	831	gallbladder	gallbladder	NN	I-NP
I-Tissue	832	842	epithelium	epithelium	NN	I-NP
O	842	843	.	.	.	O

O	844	846	On	On	IN	B-PP
O	847	850	the	the	DT	B-NP
O	851	859	contrary	contrary	NN	I-NP
O	859	860	,	,	,	O
O	861	866	there	there	EX	B-NP
O	867	870	was	be	VBD	B-VP
O	871	878	intense	intense	JJ	B-NP
O	879	887	staining	staining	NN	I-NP
O	888	891	for	for	IN	B-PP
O	892	896	HER2	HER2	NN	B-NP
O	897	899	on	on	IN	B-PP
O	900	903	the	the	DT	B-NP
B-Cellular_component	904	915	basolateral	basolateral	JJ	I-NP
I-Cellular_component	916	924	membrane	membrane	NN	I-NP
O	925	927	of	of	IN	B-PP
B-Cell	928	938	epithelial	epithelial	JJ	B-NP
I-Cell	939	944	cells	cell	NNS	I-NP
O	945	947	of	of	IN	B-PP
B-Pathological_formation	948	958	intestinal	intestinal	JJ	B-NP
I-Pathological_formation	959	969	metaplasia	metaplasia	NN	I-NP
O	970	971	(	(	(	O
O	971	973	22	22	CD	B-NP
O	973	974	/	/	SYM	O
O	974	976	24	24	CD	B-NP
O	976	977	;	;	:	O
O	978	980	91	91	CD	B-NP
O	980	981	.	.	.	O
O	981	982	7	7	CD	B-NP
O	982	983	%	%	NN	I-NP
O	983	984	)	)	)	O
O	985	988	and	and	CC	O
B-Cancer	989	998	carcinoma	carcinoma	NN	B-NP
I-Cancer	999	1001	in	in	FW	B-ADVP
I-Cancer	1002	1006	situ	situ	FW	I-ADVP
O	1007	1008	(	(	(	O
O	1008	1009	9	9	CD	B-NP
O	1009	1010	/	/	SYM	O
O	1010	1012	10	10	CD	B-NP
O	1012	1013	;	;	:	O
O	1014	1016	90	90	CD	B-NP
O	1016	1017	%	%	NN	I-NP
O	1017	1018	)	)	)	O
O	1018	1019	,	,	,	O
O	1020	1023	the	the	DT	B-NP
B-Pathological_formation	1024	1031	lesions	lesion	NNS	I-NP
O	1032	1036	that	that	WDT	B-NP
O	1037	1046	displayed	display	VBD	B-VP
O	1047	1048	a	a	DT	B-NP
O	1049	1062	significantly	significantly	RB	I-NP
O	1063	1067	high	high	JJ	I-NP
O	1068	1081	proliferation	proliferation	NN	I-NP
O	1082	1087	index	index	NN	I-NP
O	1087	1088	.	.	.	O

O	1089	1096	Protein	Protein	NN	B-NP
O	1097	1099	up	up	RB	B-ADVP
O	1099	1100	-	-	HYPH	B-NP
O	1100	1110	regulation	regulation	NN	I-NP
O	1111	1113	of	of	IN	B-PP
O	1114	1118	HER2	HER2	NN	B-NP
O	1119	1121	in	in	IN	B-PP
O	1122	1125	the	the	DT	B-NP
B-Tissue	1126	1136	epithelium	epithelium	NN	I-NP
O	1137	1141	with	with	IN	B-PP
B-Pathological_formation	1142	1152	metaplasia	metaplasia	NN	B-NP
O	1153	1155	or	or	CC	I-NP
B-Cancer	1156	1165	carcinoma	carcinoma	NN	I-NP
I-Cancer	1166	1168	in	in	FW	B-ADVP
I-Cancer	1169	1173	situ	situ	FW	I-ADVP
O	1174	1177	was	be	VBD	B-VP
O	1178	1181	not	not	RB	I-VP
O	1182	1193	accompanied	accompany	VBN	I-VP
O	1194	1196	by	by	IN	B-PP
O	1197	1201	HER2	HER2	NN	B-NP
O	1202	1206	gene	gene	NN	I-NP
O	1207	1220	amplification	amplification	NN	I-NP
O	1220	1221	.	.	.	O

O	1222	1223	A	A	DT	B-NP
O	1224	1231	similar	similar	JJ	I-NP
O	1232	1238	result	result	NN	I-NP
O	1239	1242	was	be	VBD	B-VP
O	1243	1251	observed	observe	VBN	I-VP
O	1252	1254	in	in	IN	B-PP
B-Cancer	1255	1263	invasive	invasive	JJ	B-NP
I-Cancer	1264	1274	carcinomas	carcinoma	NNS	I-NP
O	1275	1276	(	(	(	O
O	1276	1277	0	0	CD	B-NP
O	1277	1278	/	/	SYM	I-NP
O	1278	1280	12	12	CD	I-NP
O	1280	1281	)	)	)	O
O	1281	1282	.	.	.	O

O	1283	1286	The	The	DT	B-NP
O	1287	1288	B	B	NN	I-NP
O	1288	1289	(	(	(	O
O	1289	1290	1	1	CD	B-NP
O	1290	1291	)	)	)	O
O	1291	1292	R	R	NN	B-NP
O	1293	1305	distribution	distribution	NN	I-NP
O	1306	1313	pattern	pattern	NN	I-NP
O	1314	1322	mirrored	mirror	VBD	B-VP
O	1323	1327	that	that	IN	B-SBAR
O	1328	1330	of	of	IN	B-PP
O	1331	1335	HER2	HER2	NN	B-NP
O	1336	1342	except	except	IN	B-PP
O	1343	1347	that	that	IN	B-NP
O	1348	1349	B	B	NN	B-NP
O	1349	1350	(	(	(	O
O	1350	1351	1	1	CD	B-NP
O	1351	1352	)	)	)	O
O	1352	1353	R	R	NN	B-NP
O	1354	1357	was	be	VBD	B-VP
O	1358	1370	additionally	additionally	RB	I-VP
O	1371	1379	observed	observe	VBN	I-VP
O	1380	1382	in	in	IN	B-PP
O	1383	1386	the	the	DT	B-NP
B-Cancer	1387	1395	adenomas	adenoma	NNS	I-NP
O	1395	1396	.	.	.	O

O	1397	1400	The	The	DT	B-NP
O	1401	1402	B	B	NN	I-NP
O	1402	1403	(	(	(	O
O	1403	1404	1	1	CD	B-NP
O	1404	1405	)	)	)	O
O	1405	1406	R	R	NN	B-NP
O	1407	1415	appeared	appear	VBD	B-VP
O	1416	1422	either	either	CC	O
O	1423	1425	as	as	IN	B-PP
B-Organism_substance	1426	1437	cytoplasmic	cytoplasmic	JJ	B-NP
O	1438	1442	dots	dot	NNS	I-NP
O	1443	1445	or	or	CC	O
O	1446	1454	labeling	label	VBG	B-VP
O	1455	1457	on	on	IN	B-PP
O	1458	1461	the	the	DT	B-NP
B-Cellular_component	1462	1468	apical	apical	JJ	I-NP
I-Cellular_component	1469	1473	cell	cell	NN	I-NP
I-Cellular_component	1474	1482	membrane	membrane	NN	I-NP
O	1483	1485	of	of	IN	B-PP
O	1486	1489	the	the	DT	B-NP
B-Cell	1490	1495	cells	cell	NNS	I-NP
O	1496	1505	composing	compose	VBG	B-VP
O	1506	1509	the	the	DT	B-NP
B-Tissue	1510	1519	epithelia	epithelia	NN	I-NP
O	1520	1524	with	with	IN	B-PP
B-Pathological_formation	1525	1535	intestinal	intestinal	JJ	B-NP
I-Pathological_formation	1536	1546	metaplasia	metaplasia	NN	I-NP
O	1547	1548	(	(	(	O
O	1548	1550	24	24	CD	B-NP
O	1550	1551	/	/	SYM	O
O	1551	1553	24	24	CD	B-NP
O	1553	1554	;	;	:	O
O	1555	1558	100	100	CD	B-NP
O	1558	1559	%	%	NN	I-NP
O	1559	1560	)	)	)	O
O	1561	1564	and	and	CC	O
B-Cancer	1565	1574	carcinoma	carcinoma	NN	B-NP
I-Cancer	1575	1577	in	in	FW	B-ADVP
I-Cancer	1578	1582	situ	situ	FW	I-ADVP
O	1583	1584	(	(	(	O
O	1584	1586	10	10	CD	B-NP
O	1586	1587	/	/	SYM	I-NP
O	1587	1589	10	10	CD	I-NP
O	1589	1590	;	;	:	O
O	1591	1594	100	100	CD	B-NP
O	1594	1595	%	%	NN	I-NP
O	1595	1596	)	)	)	O
O	1597	1600	and	and	CC	O
O	1601	1603	in	in	IN	B-PP
O	1604	1607	the	the	DT	B-NP
B-Cell	1608	1618	epithelial	epithelial	JJ	I-NP
I-Cell	1619	1624	cells	cell	NNS	I-NP
O	1625	1627	of	of	IN	B-PP
B-Cancer	1628	1636	adenomas	adenoma	NNS	B-NP
O	1636	1637	.	.	.	O

O	1638	1640	In	In	IN	B-PP
O	1641	1649	contrast	contrast	NN	B-NP
O	1649	1650	,	,	,	O
O	1651	1655	both	both	CC	O
O	1656	1660	HER2	HER2	NN	B-NP
O	1661	1662	(	(	(	O
O	1662	1663	4	4	CD	B-NP
O	1663	1664	/	/	SYM	I-NP
O	1664	1666	12	12	CD	I-NP
O	1666	1667	;	;	:	O
O	1668	1670	33	33	CD	B-NP
O	1670	1671	%	%	NN	I-NP
O	1671	1672	)	)	)	O
O	1673	1676	and	and	CC	O
O	1677	1678	B	B	NN	B-NP
O	1678	1679	(	(	(	O
O	1679	1680	1	1	CD	O
O	1680	1681	)	)	)	O
O	1681	1682	R	R	NN	B-NP
O	1683	1684	(	(	(	O
O	1684	1685	1	1	CD	B-NP
O	1685	1686	/	/	SYM	B-NP
O	1686	1688	12	12	CD	I-NP
O	1688	1689	;	;	:	O
O	1690	1691	8	8	CD	B-NP
O	1691	1692	.	.	.	O
O	1692	1693	3	3	CD	B-NP
O	1693	1694	%	%	NN	I-NP
O	1694	1695	)	)	)	O
O	1696	1702	showed	show	VBD	B-VP
O	1703	1704	a	a	DT	B-NP
O	1705	1708	low	low	JJ	I-NP
O	1709	1719	expression	expression	NN	I-NP
O	1720	1722	in	in	IN	B-PP
B-Cancer	1723	1731	invasive	invasive	JJ	B-NP
I-Cancer	1732	1743	gallbladder	gallbladder	NN	I-NP
I-Cancer	1744	1754	carcinomas	carcinoma	NNS	I-NP
O	1754	1755	.	.	.	O

O	1756	1766	CONCLUSION	CONCLUSION	NN	B-NP
O	1766	1767	:	:	:	O
O	1768	1771	The	The	DT	B-NP
O	1772	1774	up	up	RB	I-NP
O	1774	1775	-	-	HYPH	I-NP
O	1775	1785	regulation	regulation	NN	B-NP
O	1786	1788	of	of	IN	B-PP
O	1789	1793	HER2	HER2	NN	B-NP
O	1794	1797	and	and	CC	I-NP
O	1798	1799	B	B	NN	I-NP
O	1799	1800	(	(	(	O
O	1800	1801	1	1	CD	B-NP
O	1801	1802	)	)	)	O
O	1802	1803	R	R	NN	B-NP
O	1804	1806	in	in	IN	B-PP
B-Pathological_formation	1807	1816	precursor	precursor	NN	B-NP
I-Pathological_formation	1817	1824	lesions	lesion	NNS	I-NP
O	1825	1827	of	of	IN	B-PP
B-Cancer	1828	1839	gallbladder	gallbladder	NN	B-NP
I-Cancer	1840	1849	carcinoma	carcinoma	NN	I-NP
O	1850	1858	suggests	suggest	VBZ	B-VP
O	1859	1864	cross	cross	AFX	B-NP
O	1864	1865	-	-	HYPH	I-NP
O	1865	1869	talk	talk	NN	B-NP
O	1870	1877	between	between	IN	B-PP
O	1878	1883	these	these	DT	B-NP
O	1884	1887	two	two	CD	I-NP
O	1888	1897	receptors	receptor	NNS	I-NP
O	1898	1902	that	that	WDT	B-NP
O	1903	1906	may	may	MD	B-VP
O	1907	1909	be	be	VB	I-VP
O	1910	1912	of	of	IN	B-PP
O	1913	1923	importance	importance	NN	B-NP
O	1924	1926	in	in	IN	B-PP
O	1927	1930	the	the	DT	B-NP
O	1931	1941	modulation	modulation	NN	I-NP
O	1942	1944	of	of	IN	B-PP
B-Cell	1945	1949	cell	cell	NN	B-NP
O	1950	1963	proliferation	proliferation	NN	I-NP
O	1964	1966	in	in	IN	B-PP
B-Organ	1967	1978	gallbladder	gallbladder	NN	B-NP
O	1979	1993	carcinogenesis	carcinogenesis	NN	I-NP
O	1993	1994	.	.	.	O

